C Foerch
Overview
Explore the profile of C Foerch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
434
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitz K, Brunkhorst R, de Bruin N, Mayer C, Haussler A, Ferreiros N, et al.
Acta Neuropathol Commun
. 2017 Jun;
5(1):42.
PMID: 28578681
Bioactive lipids contribute to the pathophysiology of multiple sclerosis. Here, we show that lysophosphatidic acids (LPAs) are dysregulated in multiple sclerosis (MS) and are functionally relevant in this disease. LPAs...
2.
Foerch C, Schafer J, Pfeilschifter W, Bohmann F
Nervenarzt
. 2017 Feb;
88(6):642-651.
PMID: 28188404
In recent years a considerable number of translational research studies on intracerebral hemorrhage and ischemic stroke have been published, which are characterized by a particular proximity to practical clinical questions....
3.
Brunkhorst R, Friedlaender F, Ferreiros N, Schwalm S, Koch A, Grammatikos G, et al.
Neural Plast
. 2015 Nov;
2015:503079.
PMID: 26605090
Ceramides induce important intracellular signaling pathways, modulating proliferation, migration, apoptosis, and inflammation. However, the relevance of the ceramide metabolism in the reconvalescence phase after stroke is unclear. Besides its well-known...
4.
Zeiner P, Steinmetz H, Foerch C
Nervenarzt
. 2015 Mar;
86(6):751-2.
PMID: 25791803
No abstract available.
5.
Foerch C, Pfeilschifter W, Zeiner P, Brunkhorst R
Nervenarzt
. 2014 Jul;
85(8):982-9.
PMID: 25057113
Glial fibrillary acidic protein (GFAP) is a highly brain-specific protein that is expressed in large quantities in astrocytes and has important functions in terms of maintaining and stabilizing the cytoskeleton....
6.
Pfeilschifter W, Kashefiolasl S, Lauer A, Steinmetz H, Foerch C
Neuroscience
. 2013 Jul;
250:181-8.
PMID: 23856067
Recombinant tissue-type plasminogen activator (rt-PA) is the mainstay of acute stroke treatment and the only approved medical therapy so far. Because of its fibrinolytic action, it is presumed to aggravate...
7.
Bothe A, Berkefeld J, Singer O, Foerch C, Hattingen E
Clin Neuroradiol
. 2013 Feb;
24(1):65-8.
PMID: 23392580
No abstract available.
8.
Singer O, Hamann G, Misselwitz B, Steinmetz H, Foerch C
Cerebrovasc Dis
. 2012 Feb;
33(4):316-21.
PMID: 22343969
Background: Systemic thrombolysis for acute stroke was approved by German authorities in 2002. While recombinant tissue plasminogen activator (rtPA) use first remained low, systemic thrombolysis is nowadays an established part...
9.
Thompson B, Bejot Y, Caso V, Castillo J, Christensen H, Flaherty M, et al.
Neurology
. 2010 Sep;
75(15):1333-42.
PMID: 20826714
Objectives: Antiplatelet therapy (APT) promotes bleeding; therefore, APT might worsen outcome in patients with intracerebral hemorrhage (ICH). We performed a systematic review and meta-analysis to address the hypothesis that pre-ICH...
10.
Foerch C, Montaner J, Furie K, Ning M, Lo E
Neurology
. 2009 Aug;
73(5):393-9.
PMID: 19652144
Emerging data suggest that a wide array of measurable biomarkers in blood may provide a novel window into the pathophysiology of stroke. In this review, we survey the state of...